Preclinical News and Research

RSS

Powerful new antibiotic treatment for MRSA and C. difficile bugs

MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde in Glasgow, Scotland, is developing a powerful new antibiotic treatment for resistant infections including the deadly MRSA and Clostridium difficile (C. diff.) bugs.

20 Sep 2011

Mayo Clinic, SK biopharmaceuticals collaborate to discover new ALS drugs

South Korean biotech SK biopharmaceuticals announced yesterday that they signed an agreement to collaborate with the Mayo Clinic for the discovery of new drugs targeting Amyotrophic Lateral Sclerosis.

20 Sep 2011

Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data from a preclinical study evaluating the efficacy its NDV-3 vaccine in a model of vulvovaginal candidiasis (VVC), which is primarily caused by Candida albicans.

20 Sep 2011

Preclinical studies shows EmPAC more effective than Taxol

Cornerstone Pharmaceuticals, Inc. has announced the publication of data from preclinical studies on EmPAC™, its nanoparticle reformulation of paclitaxel, in the August issue of the Journal of Nanoscience and Nanotechnology. The publication highlights data demonstrating improved safety and efficacy of EmPAC™ versus Taxol®, the generic formulation of paclitaxel and one of the most widely prescribed chemotherapies. EmPAC™ is a nanoemulsion formulation of Paclitaxel and is the lead product candidate of Cornerstone’s proprietary Emulsiphan™ cancer selective delivery nanotechnology platform. Taxol®, an injectable formulation of Paclitaxel, is currently used to treat a variety of cancers, including ovarian carcinomas, breast cancer, non-small cell lung cancer, and AIDS-related Kaposi’s sarcoma.

19 Sep 2011

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive Phase 1 data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

19 Sep 2011

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

19 Sep 2011

USPTO issues notice of allowance to Cenestra Health's omega-3 fatty acid formulations

The U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance related to Cenestra Health's high-purity omega-3 fatty acid formulations and their methods of use.

19 Sep 2011

BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine

Vaxin Inc., a clinical stage vaccine development company, today announced that it has been awarded a contract valued at up to $21.7 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) for pre-clinical assessment, final manufacturing process development and the supply of clinical materials to support an IND filing and first-in-man dose ranging study of the company's proprietary anthrax vaccine, AdVAV.

17 Sep 2011

Nanion’s automated patch clamp platforms show unparalleled results using stem cell derived cardiomyocytes

The Patchliner and the SyncroPatch 96 have successfully been used for compound analysis under current- and voltage clamp recording conditions using different stem cell-derived cardiomyocytes. The exceptional cell-platform-compatibility and the unique experimental possibilities offered by Nanion’s platforms open up whole new avenues for compound safety testing.

16 Sep 2011

Policies needed to prepare individuals, society for earlier diagnosis and high risk of Alzheimer's

The changing tide of Alzheimer's diagnosis presents new challenges to the public, physicians and lawmakers: if you could find out your Alzheimer's risk, would you want to know? How should doctors tell you your risk? And what does it mean for the many newly diagnosed Americans still in the workplace?

16 Sep 2011

Anavex announces ANAVEX pre-clinical data on Alzheimer's disease

Anavex Life Sciences Corp. will present the most recent data showing the therapeutic potential of ANAVEX compounds in animal models of Alzheimer's disease at a special symposium of the 34th annual meeting of the Japan Neuroscience Society.

16 Sep 2011

Estrogen therapy can reverse progression of pulmonary hypertension

UCLA researchers have found that the hormone estrogen may help reverse advanced pulmonary hypertension, a rare and serious condition that affects 2 to 3 million individuals in the U.S., mostly women, and can lead to heart failure.

16 Sep 2011

Potential new treatment for fragile X syndrome

Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.

16 Sep 2011

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Polyplus-transfection SA, which specializes in the development of innovative solutions for the delivery of nucleic acids in research and therapeutics, today celebrates ten years of continuous growth.

15 Sep 2011

Hengrui, Shanghai ChemPartner enter strategic development partnership for monoclonal antibodies

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner, a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies.

15 Sep 2011

VBI Vaccines completes acquisition of Epixis

VBI Vaccines (VBI), a biotechnology company dedicated to the innovative formulation, development and delivery of safe and effective vaccines, announced today that it has completed the acquisition of Epixis S.A., a French biotechnology company developing its "eVLP" platform technology for a new generation of Virus-Like Particle (VLP) vaccines.

15 Sep 2011

Positive results from PROLOR Biotech's Factor VIIa-CTP preclinical study on hemophilia

PROLOR Biotech, Inc.,, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.

15 Sep 2011

DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program

DiscoveryBioMed, Inc. (DBM), a human cell-based drug discovery company, learned recently that its Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program will be funded by the NIH. The two-year award will focus on validation and prioritization of several lead CFCL chemical classes, drugs that correct the most common cystic fibrosis (CF) disease-causing mutation.

14 Sep 2011

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.

14 Sep 2011

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

Cornell University researchers may have solved a 100-year puzzle: How to safely open and close the blood-brain barrier so that therapies to treat Alzheimer's disease, multiple sclerosis and cancers of the central nervous system might effectively be delivered.

14 Sep 2011

Preclinical News and Research

Powerful new antibiotic treatment for MRSA and C. difficile bugs

Mayo Clinic, SK biopharmaceuticals collaborate to discover new ALS drugs

Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC

Preclinical studies shows EmPAC more effective than Taxol

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

USPTO issues notice of allowance to Cenestra Health's omega-3 fatty acid formulations

BARDA awards Vaxin $21.7M contract to accelerate development of novel anthrax vaccine

Nanion’s automated patch clamp platforms show unparalleled results using stem cell derived cardiomyocytes

Policies needed to prepare individuals, society for earlier diagnosis and high risk of Alzheimer's

Anavex announces ANAVEX pre-clinical data on Alzheimer's disease

Estrogen therapy can reverse progression of pulmonary hypertension

Potential new treatment for fragile X syndrome

Polyplus-transfection appoints ten additional biologists and chemists to support multiple pre-clinical studies

Hengrui, Shanghai ChemPartner enter strategic development partnership for monoclonal antibodies

VBI Vaccines completes acquisition of Epixis

Positive results from PROLOR Biotech's Factor VIIa-CTP preclinical study on hemophilia

DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Researchers may have solved 100-year-old puzzle to safely open and close the blood-brain barrier

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics